Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 10/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751786 | 0.85 | ADRB3 (0.46) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5751173 | 0.85 | ADRB3 (0.46) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5752334 | 0.82 | SLC2A1 (0.46) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5749795 | 0.82 | ADRB3 (0.43) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5751590 | 0.81 | ADRB3 (0.45) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5753519 | 0.79 | ADRB3 (0.46) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5752090 | 0.79 | CCR9 (0.43) | ADRB3ADRB2ADRB1 | |
| SCHEMBL5752650 | 0.79 | ADRB3 (0.45) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5751830 | 0.78 | ADRB3 (0.42) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL5753040 | 0.77 | ADRB3 (0.44) | ADRB3ADRB1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | ADRB3 85/4885ADRB2 177/4885ADRB1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.